Affiliated Treatment Facilities
Contact Information
The Department of Surgical Oncology
1400 Pressler Street, Unit 1484
Houston, TX 77030
01. Doctor Overview
Doctor Overview
Dr. Paul F. Mansfield is a surgical oncologist and professor at MD Anderson Cancer Center in Houston, Texas. He has decades of experience performing surgery as a means of treating cancer patients. His primary focus is on cancers in the abdomen, including peritoneal mesothelioma.
In his practice and research, he uses minimally invasive techniques like laparoscopy. Using a small camera, this procedure lets doctors see inside a patient’s body, which can be helpful for diagnosis. Another technique he uses is heated intraperitoneal chemotherapy (HIPEC), which rinses the abdominal cavity with heated chemo drugs. This treatment usually takes place after surgery.
“My colleagues and I realize that there’s an entire patient there,” Dr. Mansfield said. “A family, and people who need an education and an understanding and, oftentimes, a long-term relationship to help get them the best outcome.”
02. Fast Facts
Doctor Fast Facts
Main Specialty: Surgical Oncology
Other Interests & Specialties: Esophageal surgery, stomach surgery, intestinal surgery, prostate surgery, colon removal, appendectomy and abdominal adhesion surgery.
Certifications, Awards & Accolades: American Board of Surgery, American Cancer Society Fellow
Education & Experience:
- Medical Degree from Sidney Kimmel Medical College at Thomas Jefferson University
- Internship in General Surgery at Pennsylvania Hospital of the University of Pennsylvania Health System
- Fellowship in Clinical Surgical Oncology at MD Anderson Cancer Center at the University of Texas
- Residency in General Surgery at Pennsylvania Hospital of the University of Pennsylvania Health System
03. Publications
Publications
HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival. Eur J Surg Oncol. 2025 Jan;51(1):108790.
Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent mucinous appendiceal adenocarcinoma: a viable treatment strategy with demonstrable benefit. Ann Surg Oncol. 2024 Jan;31(1):614–21.
Efficacy, safety, and biomarker analysis of combined pd-l1 (Atezolizumab) and vegf (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 2021 Nov;11(11):2738–47.
